Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Springworks Therapeutics Inc
(NQ:
SWTX
)
33.43
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Springworks Therapeutics Inc
< Previous
1
2
Next >
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 03, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
March 08, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
February 28, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 27, 2023
– PDUFA Action Date Set for August 27, 2023 –
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
December 27, 2022
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
September 29, 2022
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
Exposures
COVID-19
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
June 28, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.